Archive

April 2025

Browsing

Stock Market News: UK Forecast and Technical Analysis

Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628, nearly matching the 1.2% increase in the FTSE 100, driven largely by gains in mining stocks. This positive momentum is creating a bullish sentiment in the market.

The two London indices are leading the European market this morning. The DAX is up 0.7% in Germany, followed by the FTSE MIB in Italy, the CAC 40 in France, and the IBEX 35 in Spain, all of which are up 0.4%, reinforcing the optimistic outlook across Europe.

The gain for the Euro Stoxx 600 is just under 1%. Risers include Just Eat Takeaway, rising 17%; TeamViewer, the software company and owner of Kenco, JD Peet.

Among the higher risers, Wickes Group PLC, one of the UK’s listed companies, has seen a 3.3% increase in revenue despite facing difficulties retaining customers for its custom kitchen, home office installation, and bathroom services.

In the first half, this segment’s revenues were destroyed by 17%, offsetting the 1% growth in revenue in its core retail offering.

GSK Shares Decline

GSK PLC, the drugmaker listed on the FTSE 100, raised its annual earnings and sales forecasts due to strong second-quarter performance from HIV and cancer treatments, but the stock is currently down 2.5%.

Core EPS profits are now expected to increase by 10-12% in 2024, up from the previous guidance of 8-10%. Meanwhile, the overall profits are expected to increase by 7-9%, compared to the earlier estimate of 5-7%.

Nonetheless, there were some omissions in the data: vaccination profit fell 9% short of expectations as shingles treatment Shingrix was a 20% disappointment as US sales plummeted 36%.

This is due to decreased demand and inventory reductions. However, it is important to note that international sales make up about 64% of total revenue.

General medicine, oncology, and HIV all performed better than anticipated.

GSK/GBX 5-Day Chart

Growth Expectation For FTSE 250

In the last five years, Greggs’ shares have increased by 40%, outpacing the FTSE 250 London stock. The company’s first-half (H1) results have given them an additional 5% boost.

The most recent data shows a 16% increase in profit before taxes and a 14% increase in sales.

However, despite these gains, projections indicate a minor decline in Greggs’ EPS for the full year 2024. However, the company’s first-half revenue increased by only 15%.

It is a basic diluted estimate that does not account for anomalies. However, it raises the possibility that projections are simply exaggerating the situation.

Thanks to these expenditures and a well-defined expansion plan, Greggs has produced substantial returns for its owners.

For the 2023 fiscal year, Greggs reported record yearly sales of £1.8 billion and a profit before taxes of £188.3 million.

The company also disclosed a significant capital investment program aimed at enhancing its manufacturing capacity and expanding its capacity to accommodate approximately 3,500 stores throughout the United Kingdom.

UK Stock Market Today: FTSE Stock Surge

Among the top risers in the FTSE, Antofagasta PLC and Rio Tinto have shown significant gains. Antofagasta PLC saw notable gains despite no specific news being released. Rio Tinto’s positive results, which included a 1.8% increase in first-half profit, contributed to a 1% rise in its shares and may have influenced the broader market.

More significantly, there are rumours that the Anglo-Australian miner Antofagasta is eyeing a major opportunity in the copper industry, further boosting investor confidence.

The Footsie has continued to rise, hitting a two-month peak of nearly 8,374 following a 1.2% increase. This is the highest value for the London standard since May 22nd, topping 8,368.

HSBC Makes a £3 Billion Buyback

Following a largely flat first half of the year, HSBC Holdings PLC announced an additional interim dividend and a £3 billion share buyback.

For the first half of 2024, the £0.10 per share dividend will equate to 20 cents, unchanged from the previous year. The share buyback is anticipated to be finished in three months.

The bank, with a focus on Asia, reported a first-half pre-tax profit of $21.6 billion, which was marginally lower than the same period last year, even though revenue increased 1% to $37.3 billion and certain “strategic transactions” had a net positive revenue impact of $0.2 billion.

The second quarter’s $16.5 billion in revenues exceeded analysts’ expectations, and the quarter’s $8.9 billion profit before taxes was significantly more than the $7.8 billion they had predicted.

Despite being lower than the 1.53% consensus estimate, the net interest margin improved from 1.7% to 1.62% a year ago due to an increase in the finance cost of average profit liabilities. These developments are significant for the stock market news UK, as they may influence investor sentiment and market trends.

FTSE 250 Share Price

  • Value: 21,572.34
  • Net Variation: 139.83
  • High/Low: 21,649.47 / 21,430.07
  • Previously closed price: 21,432.51
  • 52WK range: 16,783.09 – 21,432.51
  • Launch date: October 12th 1992
  • Constituents number: 250
  • Net MCap: 324,478
  • Dividend Yield: 3.35%
  • Average: 1,298
  • Largest: 4,059
  • Smallest: 81
  • Median: 1,085

FTSE 100 Share Price

  • Value: 8,390.33
  • Previous Close: 8,292.35
  • Open Price: 8,292.35
  • Day low: 8,235.55
  • Day High: 8,297.92
  • 52-week low: 7,215.76
  • 52-week high: 8,474.41

In summary, today’s gains on the stock market news UK are remarkable, as the FTSE 100 and FTSE 250 indices both saw an increase. Mining stocks, especially in the FTSE 100, have primarily driven these gains. Major indices have also increased throughout Europe, indicating an optimistic trend in the market.

While GSK continues to face difficulties even after increasing its earnings projections, Greggs has shown remarkable growth in both its stock price as well as profitability. Despite a little fluctuation in its profit margins, HSBC’s announcement of a significant share buyback and dividend demonstrates the strength of its financial position.

The post Stock Market News UK Update: FTSE 100 & 250 Rise appeared first on FinanceBrokerage.

WASHINGTON — Boeing CEO Kelly Ortberg told senators on Wednesday that he’s happy with the company’s progress improving manufacturing and safety practices following several accidents, including a near catastrophe last year.

Ortberg faced questioning from the Senate Commerce Committee about how the company will ensure that it doesn’t repeat past accidents or manufacturing defects, in his first hearing since he became CEO last August, tasked with turning the manufacturer around.

Sen. Ted Cruz, R.-Texas, the committee’s chairman, said he wants Boeing to succeed and invited company managers and factory workers to report to him their opinions on its turnaround plan. “Consider my door open,” he said.

Ortberg acknowledged the company still has more to do.

“Boeing has made serious missteps in recent years — and it is unacceptable. In response, we have made sweeping changes to the people, processes, and overall structure of our company,” Ortberg said in his testimony. “While there is still work ahead of us, these profound changes are underpinned by the deep commitment from all of us to the safety of our products and services.”

Boeing CEO Kelly Ortberg testifies on Capitol Hill on April 2.Brendan Smialowski / AFP – Getty Images

Boeing executives have worked for years to put the lasting impact of two fatal crashes of its best-selling Max plane behind it. 

Ortberg said Boeing is in discussions with the Justice Department for a revised plea agreement stemming from a federal fraud charge in the development of Boeing’s best-selling 737 Maxes. The previous plea deal, reached last July, was later rejected by a federal judge, who last month set a trial date for June 23 if a new deal isn’t reached.

Boeing had agreed to plead guilty to conspiring to defraud the U.S. government, pay up to $487.2 million and install a corporate monitor at the company for three years.

“We’re in the process right now of going back with the DOJ and coming up with an alternate agreement,” Ortberg said during the hearing. “I want this resolved as fast as anybody. We’re still in discussions and hopefully we’ll have a new agreement here soon.”

Asked by Sen. Maria Cantwell, the ranking Democrat on the committee, whether he had an issue with having a corporate monitor, Ortberg replied: “I don’t personally have a problem, no.”

Ortberg and other Boeing executives have recently outlined improvements across the manufacturer’s production lines, such as reducing defects and risks from so-called traveled works, or doing tasks out of sequence, in recent months, as well as wins like a contract worth more than $20 billion to build the United States’ next generation fighter jet.

But lawmakers and regulators have maintained heightened scrutiny on the company, a top U.S. exporter.

“Boeing has been a great American manufacturer and all of us should want to see it thrive,” Sen. Ted Cruz, a Texas Republican and chairman of the committee, said in a statement in February announcing the hearing. “Given Boeing’s past missteps and problems, the flying public deserves to hear what changes are being made to rehabilitate the company’s tarnished reputation.”

The Federal Aviation Administration last year capped Boeing’s production of its 737 Max planes at 38 a month following the January 2024 door plug blowout. The agency plans to keep that limit in place, though Boeing is producing below that level.

Ortberg said at the hearing Wednesday that the company could work up to production rate of 38 Max planes a month or even higher sometime this year, but said Boeing wouldn’t push it if the production line isn’t stable.

Acting FAA Administrator Chris Rocheleau said at a Senate hearing last week that the agency’s oversight of the company “extends to ongoing monitoring of Boeing’s manufacturing practices, maintenance procedures, and software updates.”

This post appeared first on NBC NEWS

Retailers and brands have turned to Vietnam to manufacture goods from sneakers to couches while moving some or all production out of China.

For years, China’s southern neighbor became a popular alternative for companies trying to avoid the crossfire of U.S. trade tensions with Beijing. Now, as President Donald Trump expands his tariff targets, they can no longer steer clear.

Trump said he will put a 46% duty on imports from Vietnam as part of a new wave of global levies announced Wednesday. That could soon raise costs for major corporations in the apparel, furniture and toy space, and some of them may pass those increases to consumers in the form of price hikes. The tariffs on Vietnam take effect on April 9.

China exported more goods to the U.S. than any other country for more than two decades, but Mexico surpassed China as the top source in 2023. China is now the second largest supplier to the U.S., accounting for $438.9 billion worth of goods in 2024, according to government data from the Office of the U.S. Trade Representative.

For companies that have looked to diversify the countries they rely on for production and reduce risks from trade conflicts with China, Vietnam has also become a popular place to go. Imports from Vietnam grew to $136.6 billion in 2024, up about 19% from 2023, according to the Office of the U.S. Trade Representative.

On the other hand, imports from China rose only 2.8% from 2023 to 2024, according to government data. Imports from China dropped about 18% last year when compared to 2022, when the U.S. brought in $536.3 billion in goods from the country.

The duties will hit companies at a time when many consumers have become value-conscious and selective about spending due to persistent inflation and concerns about the economy. While it is unclear now which companies will raise prices due to the tariffs, businesses may be reluctant to shoulder the higher costs as they forecast lackluster spending in the months ahead.

Some household names will feel the pinch from Vietnam tariffs. Nike manufacturers about half of its footwear in China and Vietnam, with about 25% coming from Vietnam. Trump will put a 34% tariff on top of existing 20% duties on imports from China, for an apparent rate of 54%, a White House official told CNBC.

The tariffs would be yet another headwind for the sneaker and athletic apparel giant, which already delivered a disappointing forecast for the current quarter. That guidance, which projects a double-digit percentage sales decline in the three-month period, included the estimated impact from tariffs on imports from China and Mexico.

Expanded tariffs could stall or slow Nike’s efforts to revive its brand and improve sales under its new CEO Elliott Hill, a company veteran who took the helm last fall.

Nike shares dropped more than 6% in extended trading Wednesday. Adidas and other major footwear players also rely heavily on Vietnam.

The two companies did not immediately respond to CNBC’s request for comment.

Nearly a third of footwear imports in the U.S. came from Vietnam in 2023, the most recent full-year data available, according to the Footwear Distributors and Retailers of America, an industry trade group.

Steve Madden, for example, said on an earnings call in early November that it would slash its imports to the U.S. from China by as much as 45% over the next year. The footwear maker made that announcement just days after Trump’s presidential victory, following his campaign trail promises to impose steep tariffs on countries like China.

Yet one of the nations Steve Madden has accelerated its move to is Vietnam, along with Cambodia, Mexico and Brazil, CEO Edward Rosenfeld said at the time on the earnings call.

Vietnam was the second largest country for suppliers of Ugg and Hoka parent company Deckers Brands as of this month. The company has 68 supply chain partners in Vietnam, which is surpassed only by its 125 suppliers in China. Deckers shares dropped nearly 9% in extended trading. The company did not immediately respond to a request for comment.

VF Corporation, which is made up of footwear, apparel and accessories brands including The North Face, Timberland, Vans and Jansport, has a heavy reliance on China and Vietnam, too. About 38% of its suppliers are in China and 17% are in Vietnam, adding up to 55% of exposure across the two countries, according to a manufacturing disclosure from December.

The company’s shares dropped more than 8% in extended trading Wednesday. VF declined to comment, citing its quiet period before its upcoming earnings report.

The furniture industry has also ramped up its reliance on Vietnam.

In 2023, 26.5% of U.S. furniture imports came from the country, close behind the 29% coming from China, according to data from the Home Furnishings Association, a trade group that lobbies on behalf of home goods retailers. The group cited investment banking firm Mann, Armistead & Epperson — one of the furniture industry’s top sources for data.

Taken together, that means about 56% of U.S. furniture imports come from both regions combined.

On an earnings call in February, Wayfair CEO Niraj Shah said the shift to countries outside of China has been “a growing trend” since Trump enacted tariffs during his first administration.

He said places like Cambodia, Indonesia, Thailand, the Philippines and Vietnam “have grown as places where folks have factories and where our goods are coming from.”

Wayfair’s stock plunged about 12% in extended trading. In a statement, Wayfair said it is “closely monitoring the evolving trade landscape.” The company added it is “well-positioned to continue offering customers the best possible combination of value, assortment, and experience.”

Toymakers have also leaned on Vietnam to make more merchandise that’s imported and sold to kids and adults across the U.S. Hasbro, SpinMaster, Mattel and Crayola are among the companies that work with GFT Group, one of the largest toy manufacturers in the Southeast Asia.

In addition to long-established manufacturing facilities in China, GFT currently has five production facilities in northern Vietnam that employ over 15,000 workers.

On a call in early March, Funko Chief Financial Officer Yves LePendeven said the company, which is known for its big-eyed plastic collectibles called Pops, was working hard to control what it could in the year ahead. That includes trying to offset tariffs by “renegotiating factory costs, accelerating our shift in production to other sourcing countries, and implementing pricing adjustments,” he said.

On the call, he said about a third of Funko’s global product purchases come from China. He didn’t name the countries that Funko was moving production to, but it is a customer of GFT Group.

Those toymakers did not immediately respond to CNBC’s requests for comment.

Curtis McGill is the co-founder of Hey Buddy Hey Pal, a toy company that specializes in Easter egg decorating kits. He said he expects the 46% tariffs to raise toy costs in the U.S., but added companies will likely be negotiating with suppliers in Vietnam to try to mitigate those hikes.

“A lot of manufacturers and the actual toy companies have been already having conversations with manufacturing plants having to to help in some regards, because the toy companies are getting pressure to try and maintain prices on this side from the retailers,” McGill said.

For companies, including apparel makers, the new tariff policies have raised questions about whether — and where — to potentially move their manufacturing. Last month, an investor asked American Eagle Outfitters about its exposure to Vietnam on its most recent earnings call.

Chief Financial Officer Michael Mathias said the jeans and apparel brand’s production is similar in Vietnam and China, with “high-teens to 20%” of production in each of those countries. He said the company aims to trim that back to single-digits by the back half of the year.

American Eagle shares dipped more than 5% on Wednesday. The company did not immediately respond to CNBC’s request for comment.

Yet both Mathias and American Eagle CEO Jay Schottenstein said on the company’s last earnings call that it will be crucial to stay flexible, while waiting to see how tariffs would play out and which countries would be targeted.

Schottenstein referred to eight years ago during the first Trump administration, when American Eagle also faced challenges and had to figure out a new plan.

Schottenstein said there’s another shift coming, but “nobody knows what the story is yet.”

“I wouldn’t be rushing,” he said. “You go rush, where am I rushing to? I don’t know where I’m rushing to.”

Peter Baum is the chief financial officer and chief operation officer of Baum Essex, a New York-based manufacturer with licenses to make products for brands like Nautica, Betsey Johnson and Steve Madden. During the first Trump administration in 2019, Baum moved factories from from China to the Philippines, Cambodia, Vietnam and India.

He told CNBC on Wednesday that the reciprocal tariffs would do massive damage to his company.

“This is how you start a global depression. After 80 years and five generations Trump just put us out of business,” Baum said.

— CNBC’s Sarah Whitten, Jason Gewirtz and Eamon Javers contributed to this report.

This post appeared first on NBC NEWS

As precious metals surge on safe-haven demand, some gold mining companies are following suit. One standout is AngloGold Ashanti Ltd. (AU), which has been riding this upward momentum.

Recently, AU showed up among the Top 10 Large Cap category in the StockCharts Technical Rank (SCTR) Reports, indicating that it’s among the top large-cap stocks showing bullish technical strength across multiple timeframes and indicators.

FIGURE 1. SCREENSHOT OF SCTR REPORTS ON MONDAY MORNING. AU, which held the #6 spot at the time of the screenshot, had an ultra-bullish SCTR score of 99.3.

Unless you follow gold miners, you may not know much about AU. But here’s the skinny: AngloGold Ashanti Ltd. is a global independent mining company that’s incorporated in the UK but headquartered in Colorado, US. 

AU’s recent surge can be attributed to several factors, including rising gold prices, strong financials, recent strategic acquisitions, revised dividend policy, and general investor shift to safe havens.

If you’re unfamiliar with the stock, a good starting point is to compare its relative performance against its industry (Dow Jones Gold Mining Index or $DJUSPM) and spot gold price performance ($GOLD). The PerfChart below displays AU’s performance relative to the industry and gold’s price over the past year.

FIGURE 2. PERFCHARTS OF AU, DJ GOLD MINING INDEX, AND GOLD. AU began outperforming its overall industry and gold’s performance in late January.

AU and $DJUSPM have shown volatile, back-and-forth price action over the past 12 months, but AU began taking the lead in late January, surpassing both in comparative terms.

Now that you have a comparative view, let’s take a longer-term look at AU’s price action. Here’s a monthly chart spanning 20 years. Why so long? I had to go this far back to plot long-term resistance levels.

FIGURE 3. MONTHLY CHART OF AU. The stock just broke above a resistance range between $35 and $37, but there are plenty more technical headwinds above.

AU appears to be soaring at relatively high valuations and is running up against a major resistance range between $42 and $45. What adds weight to the long-term bullish case of AU’s current valuations is the rising Ichimoku Cloud, indicating a long-term uptrend projection (26 months) and a Relative Strength Index (RSI) reading that is rising but not quite overbought. Another thing to note, which is interesting, is that every time the RSI crossed 70, AU reversed to the downside. 

Despite this bullish projection, keep in mind that AU could still pull back—while remaining in a long-term uptrend—and decline to as low as $22.50 before rebounding. This level marks a key swing low and aligns with the top of the Ichimoku Cloud’s support range.

That gives us a long-term perspective. What about the near term? Might there be a favorable entry point for those looking to go long, or is AU technically overbought? 

Let’s shift over to a daily chart.

FIGURE 4. DAILY CHART OF AU. Pay attention to the most recent swing high and low.

The Gold Miners Bullish Percent Index (BPI) indicates strong bullish breadth as over 89% of gold mining stocks are rallying and triggering P&F buy signals. However, this can also indicate potential overbought levels, and the RSI supports this reading, as it, too, is over the 70 threshold (caveat: a stock can continue to rally for an extended period despite being overbought).

Volume-wise, note how accumulation preceded AU’s rally as far back as September when the Accumulation/Distribution Line (ADL) shown in orange began rising above AU’s price as if the smart money began accumulating the stock as it continued to decline before rebounding. AU currently trades above the ADL line, which could signal a near-term pullback. 

Pay attention to AU’s price relative to its most recent swing high (magenta dotted line) and swing low (blue dotted line). I plotted a ZigZag line to make these swing points clear. 

  • If AU pulls back, it may find support at the swing high near $33. What’s more important is that the stock price must hold above the swing low near $28 to sustain the current uptrend.
  • Expect resistance between $42 and $45 (as mentioned earlier when analyzing the monthly chart).

What Should You Do?

If you’re already in AU and not necessarily committed to the long term, consider tightening your stops or scaling out partial profits as the stock approaches the $42–$45 resistance zone. The RSI above 70 and elevated breadth readings across the gold mining sector suggest short-term overbought conditions, making a pullback likely—even within a broader uptrend. Watch for any bearish divergences or volume reversals, and use a bounce from $28 or $33 to potentially add to your position.

If you’re looking to enter, patience may pay. A retracement to the $33 support zone—or the swing low at $28 if sentiment reverses sharply—could offer a more favorable risk-reward entry. Keep in mind that a break below $28 would weaken the current technical structure and could open the door to a deeper correction, potentially down to $22.50.

For long-term investors, AU still holds promise. The rising monthly Ichimoku Cloud you saw in the monthly chart, strong accumulation trends, and outperformance vs. peers support a bullish longer-term case. But stay disciplined, and keep an ear on economic developments that may have a longer-term impact. Consider using a tiered entry approach rather than chasing highs.

In short, AU’s long-term momentum is intact, but don’t ignore the warning signs of a short-term cooldown. Stay tactical—ride the trend, but always protect your capital!

At the Close

While AU continues to ride the wave of bullish sentiment in the gold sector, a few of its technical indicators, appearing seemingly stretched, hint at a possible short-term breather. Long-term prospects remain intact, but near-term caution is warranted.


Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

Did you know you can generate more than a 5% monthly yield by utilizing an options strategy? 

In this educational video, Tony Zhang walks you through an income-generating options strategy using the OptionsPlay Strategy Center on StockCharts.com.

Learn how to select the right stocks, identify strike prices and expiration dates, analyze various outcomes, and manage your trades.

Armed with this knowledge, you will never want to miss out on the opportunity to generate income from your portfolio. 

This video premiered on April 1, 2025.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,243.7 as of March 31, 2025, further growth could be in store in the future.

According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.036 trillion.

Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

Data was gathered on March 31, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.

1. Bright Minds Biosciences (NASDAQ:DRUG)

Company Profile

Year-over-year gain: 2,942.02 percent
Market cap: US$254.99 million
Share price: US$36.20

Bright Minds Biosciences is developing novel treatments for pain and neuropsychiatric disorders such as epilepsy, post-traumatic stress disorder and difficult-to-treat depression.The company’s platform includes serotonin agonists designed to provide powerful therapeutic benefits while minimizing side effects.

Bright Minds is currently in Phase 2 clinical trials for BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy.

Bright Minds’ share price rocketed upward in the fourth quarter of last year, shooting up from US$2.49 to US$38.49 in one day on October 15. The company issued a press release at the time, stating it was ‘unaware of any material changes in the company’s operations’ that would have contributed to such a rally.

The outperformance appears to be related to the October 14 news that Danish pharma company H. Lundbeck was to acquire Longboard Pharma, a company developing a 5-HT2C receptor agonist, for US$60 per share.

A few days later, Bright Minds announced a non-brokered private placement of US$35 million, which sent shares up to US$47.21 on October 18.

That same month, the company shared its collaboration with Firefly Neuroscience (NASDAQ:AIFF) to use Firefly’s Brain Network Analytics technology platform to provide a full analysis of the electroencephalogram data from Bright Minds’ BMB-101 Phase 2 clinical trial. This follows the pair’s previous successful collaboration to analyze data from Bright Minds’ first-in-human Phase 1 study of BMB-101.

In March 2025, Bright Minds expanded its Scientific Advisory Board with the addition of five experts in epilepsy research.

Bright Minds’ share price reached US$55.77, its peak for the past year, on November 6.

2. Monopar Therapeutics (NASDAQ:MNPR)

Company Profile

Year-over-year gain: 924.54 percent
Market cap: US$220.3 million
Share price: US$36.10

Clinical-stage biotech Monopar Therapeutics’ main drug candidate is its late-stage ALXN-1840 for Wilson disease. Its pipeline also includes radiopharma programs such as Phase 1-stage MNPR-101-Zr for imaging advanced cancers, as well as Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers.

Shares in Monopar spiked by more than 600 percent on October 24, 2024, to US$32.66 following its news release detailing its exclusive worldwide licensing agreement with Alexion, AstraZeneca’s (NASDAQ:AZN) Rare Disease unit, for ALXN-1840, a drug candidate for Wilson disease that met its primary endpoints in its Phase 3 clinical trial. Going forward, Monopar will be responsible for all future global development and commercialization activities.

Further positive news flow in December continued to drive the company’s stock value. Early in the month, the company shared that the first patient was dosed with MNPR-101-Lu in its Phase 1a trial for the radiopharmaceutical. A few weeks later, Monopar announced the launch of a US$40 million concurrent public offering and private placement. After having fallen back to the US$22 range, shares in the company climbed to US$30.68 on December 17, 2024.

Positive sentiment in the company and the biotech market would later drive the stock up to its yearly high of US$51.89 on February 10, 2025. Monopar released its Q4 and full-year 2024 results on March 31.

3. Candel Therapeutics (NASDAQ:CADL)

Company Profile

Year-over-year gain: 268.3 percent
Market cap: US$262.39 million
Share price: US$5.64

Candel Therapeutics is a biotech company focused on developing oncology treatments. The company’s pipeline includes two clinical-stage multimodal biological immunotherapy platforms.

Candel’s lead product candidate, CAN-2409, is in a Phase 2 clinical trial in non-small cell lung cancer and borderline resectable pancreatic cancer, as well as Phase 2 and 3 trials for localized, non-metastatic prostate cancer.

The company had a number wins with the US Food and Drug Administration (FDA) in 2024. In February and May, respectively, Candel’s CAN-3110 received regulatory approval for fast-track designation and orphan drug designation for the treatment of recurrent high-grade glioma.

The agency also granted Candel orphan drug designation for CAN-2409 for the treatment of pancreatic cancer in April 2024. Positive interim data for the trial on pancreatic cancer released that month, sent the company’s share price spiking upward. It ultimately climbed to its 2024 high point of US$14.00 on May 15, 2024.

So far in 2025, Candel’s share price has traded as high as US$12.21 on February 20. In its January corporate update, the company shared its goals for the year, including aiming for Q4 for reporting overall survival data in patients with recurrent high-grade glioma from its ongoing phase 1b trial that is evaluating multiple doses of CAN-3110.

4. Tiziana Life Sciences (NASDAQ:TLSA)

Company Profile

Year-over-year gain: 154.76 percent
Market cap: US$119.51 million
Share price: US$1.08

Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous (IV) delivery. Tiziana’s lead candidate is intranasal foralumab, which it says is the only fully human anti-CD3 mAb currently in clinical development.

On May 31, 2024, shares in Tiziana broke above US$1 after a series of positive news flow for the company. This included positive clinical results from its intermediate sized Expanded Access Program for non-active secondary progressive multiple sclerosis patients, which demonstrated multiple improvements in foralumab-treated patients, as well as its submission of an orphan drug designation application to the FDA for intranasal foralumab for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS).

While Tiazana’s share price slid back down below US$1 per share by mid-June 2024, news that the FDA granted fast track designation to Tiziana intranasal foralumab for the treatment of na-SPMS gave it a much needed boost to the upside. By August 12, the stock’s value had risen to US$1.45 per share.

Tiziana Life Sciences shares reached a yearly peak of US$1.69 on March 7, 2025, after the company filed its investigational new drug application to the FDA for a phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association.

5. Benitec Biopharma (NASDAQ:BNTC)

Company Profile

Year-over-year gain: 149.71 percent
Market cap: US$331.43 million
Share price: US$13.01

California-based Benitec Biopharma is advancing novel genetic medicines via its proprietary “Silence and Replace” DNA-directed RNA interference platform. The company is currently focused on developing therapeutics for chronic and life-threatening conditions, including oculopharyngeal muscular dystrophy (OPMD).

Its drug candidate BB-301 was granted orphan drug designation by the FDA and the European Medicines Agency. Benitec is well funded to advance its BB-301 clinical development program through the end of 2025.

Benitec’s share price benefited from its first bump of the past year, after the company released its fiscal year Q3 2024 update in mid-May highlighting its achievements over the quarter. This included the closing of a US$40 million private placement. Benitec’s stock value hit US$10.47 per share on May 20, 2024.

Later in the fall, the company reported positive data from two patients with OPMD treated with low-dose BB-301 in phase 1b/2a study, showing the clinical trial is meeting key safety and efficacy endpoints. Shares hit another high of US$11.22 on October 17, 2024.

Benitec’s share price hit US$16.79, its highest yearly value to date, on March 20, 2025, a day after the company released positive interim clinical results for three patients with OPMD treated with BB-301 in phase 1b/2a study.

“The sixth and final Subject of Cohort 1 will be treated with BB-301 in the second calendar quarter of this year, and we are highly optimistic about the potential for continued benefit in Subjects enrolled in the ongoing clinical study,” said Jerel A. Banks, Benitec Executive Chairman and CEO.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

StrategX Elements Corp. (CSE: STGX) (‘StrategX’ or the ‘Company’) announces that Gary Wong has stepped down from his role as the Company’s Vice President of Exploration. While Gary is transitioning from this position, he will continue to contribute to other capacities, bringing his expertise and leadership to key projects. The Board would like to thank Gary for his efforts and contributions over the past two years.

About StrategX
StrategX is an exploration company focused on discovering critical metals in northern Canada. With projects on the East Arm of the Great Slave Lake (Northwest Territories) and the Melville Peninsula (Nunavut), the Company is pioneering new district-scale discoveries in these underexplored regions. By integrating historical data with modern exploration techniques, StrategX provides investors with a unique opportunity to participate in discovering essential metals crucial to electrification, global green energy, and supply chain security.

On Behalf of the Board of Directors

Darren G. Bahrey
CEO, President & Director

For further information, please contact:

StrategX Elements Corp.
info@strategXcorp.com
Phone: 604.379.5515

For further information about the Company, please visit our website at www.strategXcorp.com.

Neither the Canadian Securities Exchange nor its regulation services accept responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Not for distribution to United States newswire services or for dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247050

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

Stock Market News: UK Forecast and Technical Analysis

Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628, nearly matching the 1.2% increase in the FTSE 100, driven largely by gains in mining stocks. This positive momentum is creating a bullish sentiment in the market.

The two London indices are leading the European market this morning. The DAX is up 0.7% in Germany, followed by the FTSE MIB in Italy, the CAC 40 in France, and the IBEX 35 in Spain, all of which are up 0.4%, reinforcing the optimistic outlook across Europe.

The gain for the Euro Stoxx 600 is just under 1%. Risers include Just Eat Takeaway, rising 17%; TeamViewer, the software company and owner of Kenco, JD Peet.

Among the higher risers, Wickes Group PLC, one of the UK’s listed companies, has seen a 3.3% increase in revenue despite facing difficulties retaining customers for its custom kitchen, home office installation, and bathroom services.

In the first half, this segment’s revenues were destroyed by 17%, offsetting the 1% growth in revenue in its core retail offering.

GSK Shares Decline

GSK PLC, the drugmaker listed on the FTSE 100, raised its annual earnings and sales forecasts due to strong second-quarter performance from HIV and cancer treatments, but the stock is currently down 2.5%.

Core EPS profits are now expected to increase by 10-12% in 2024, up from the previous guidance of 8-10%. Meanwhile, the overall profits are expected to increase by 7-9%, compared to the earlier estimate of 5-7%.

Nonetheless, there were some omissions in the data: vaccination profit fell 9% short of expectations as shingles treatment Shingrix was a 20% disappointment as US sales plummeted 36%.

This is due to decreased demand and inventory reductions. However, it is important to note that international sales make up about 64% of total revenue.

General medicine, oncology, and HIV all performed better than anticipated.

GSK/GBX 5-Day Chart

Growth Expectation For FTSE 250

In the last five years, Greggs’ shares have increased by 40%, outpacing the FTSE 250 London stock. The company’s first-half (H1) results have given them an additional 5% boost.

The most recent data shows a 16% increase in profit before taxes and a 14% increase in sales.

However, despite these gains, projections indicate a minor decline in Greggs’ EPS for the full year 2024. However, the company’s first-half revenue increased by only 15%.

It is a basic diluted estimate that does not account for anomalies. However, it raises the possibility that projections are simply exaggerating the situation.

Thanks to these expenditures and a well-defined expansion plan, Greggs has produced substantial returns for its owners.

For the 2023 fiscal year, Greggs reported record yearly sales of £1.8 billion and a profit before taxes of £188.3 million.

The company also disclosed a significant capital investment program aimed at enhancing its manufacturing capacity and expanding its capacity to accommodate approximately 3,500 stores throughout the United Kingdom.

UK Stock Market Today: FTSE Stock Surge

Among the top risers in the FTSE, Antofagasta PLC and Rio Tinto have shown significant gains. Antofagasta PLC saw notable gains despite no specific news being released. Rio Tinto’s positive results, which included a 1.8% increase in first-half profit, contributed to a 1% rise in its shares and may have influenced the broader market.

More significantly, there are rumours that the Anglo-Australian miner Antofagasta is eyeing a major opportunity in the copper industry, further boosting investor confidence.

The Footsie has continued to rise, hitting a two-month peak of nearly 8,374 following a 1.2% increase. This is the highest value for the London standard since May 22nd, topping 8,368.

HSBC Makes a £3 Billion Buyback

Following a largely flat first half of the year, HSBC Holdings PLC announced an additional interim dividend and a £3 billion share buyback.

For the first half of 2024, the £0.10 per share dividend will equate to 20 cents, unchanged from the previous year. The share buyback is anticipated to be finished in three months.

The bank, with a focus on Asia, reported a first-half pre-tax profit of $21.6 billion, which was marginally lower than the same period last year, even though revenue increased 1% to $37.3 billion and certain “strategic transactions” had a net positive revenue impact of $0.2 billion.

The second quarter’s $16.5 billion in revenues exceeded analysts’ expectations, and the quarter’s $8.9 billion profit before taxes was significantly more than the $7.8 billion they had predicted.

Despite being lower than the 1.53% consensus estimate, the net interest margin improved from 1.7% to 1.62% a year ago due to an increase in the finance cost of average profit liabilities. These developments are significant for the stock market news UK, as they may influence investor sentiment and market trends.

FTSE 250 Share Price

  • Value: 21,572.34
  • Net Variation: 139.83
  • High/Low: 21,649.47 / 21,430.07
  • Previously closed price: 21,432.51
  • 52WK range: 16,783.09 – 21,432.51
  • Launch date: October 12th 1992
  • Constituents number: 250
  • Net MCap: 324,478
  • Dividend Yield: 3.35%
  • Average: 1,298
  • Largest: 4,059
  • Smallest: 81
  • Median: 1,085

FTSE 100 Share Price

  • Value: 8,390.33
  • Previous Close: 8,292.35
  • Open Price: 8,292.35
  • Day low: 8,235.55
  • Day High: 8,297.92
  • 52-week low: 7,215.76
  • 52-week high: 8,474.41

In summary, today’s gains on the stock market news UK are remarkable, as the FTSE 100 and FTSE 250 indices both saw an increase. Mining stocks, especially in the FTSE 100, have primarily driven these gains. Major indices have also increased throughout Europe, indicating an optimistic trend in the market.

While GSK continues to face difficulties even after increasing its earnings projections, Greggs has shown remarkable growth in both its stock price as well as profitability. Despite a little fluctuation in its profit margins, HSBC’s announcement of a significant share buyback and dividend demonstrates the strength of its financial position.

The post Stock Market News UK Update: FTSE 100 & 250 Rise appeared first on FinanceBrokerage.

Stock Market News: UK Forecast and Technical Analysis

Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628, nearly matching the 1.2% increase in the FTSE 100, driven largely by gains in mining stocks. This positive momentum is creating a bullish sentiment in the market.

The two London indices are leading the European market this morning. The DAX is up 0.7% in Germany, followed by the FTSE MIB in Italy, the CAC 40 in France, and the IBEX 35 in Spain, all of which are up 0.4%, reinforcing the optimistic outlook across Europe.

The gain for the Euro Stoxx 600 is just under 1%. Risers include Just Eat Takeaway, rising 17%; TeamViewer, the software company and owner of Kenco, JD Peet.

Among the higher risers, Wickes Group PLC, one of the UK’s listed companies, has seen a 3.3% increase in revenue despite facing difficulties retaining customers for its custom kitchen, home office installation, and bathroom services.

In the first half, this segment’s revenues were destroyed by 17%, offsetting the 1% growth in revenue in its core retail offering.

GSK Shares Decline

GSK PLC, the drugmaker listed on the FTSE 100, raised its annual earnings and sales forecasts due to strong second-quarter performance from HIV and cancer treatments, but the stock is currently down 2.5%.

Core EPS profits are now expected to increase by 10-12% in 2024, up from the previous guidance of 8-10%. Meanwhile, the overall profits are expected to increase by 7-9%, compared to the earlier estimate of 5-7%.

Nonetheless, there were some omissions in the data: vaccination profit fell 9% short of expectations as shingles treatment Shingrix was a 20% disappointment as US sales plummeted 36%.

This is due to decreased demand and inventory reductions. However, it is important to note that international sales make up about 64% of total revenue.

General medicine, oncology, and HIV all performed better than anticipated.

GSK/GBX 5-Day Chart

Growth Expectation For FTSE 250

In the last five years, Greggs’ shares have increased by 40%, outpacing the FTSE 250 London stock. The company’s first-half (H1) results have given them an additional 5% boost.

The most recent data shows a 16% increase in profit before taxes and a 14% increase in sales.

However, despite these gains, projections indicate a minor decline in Greggs’ EPS for the full year 2024. However, the company’s first-half revenue increased by only 15%.

It is a basic diluted estimate that does not account for anomalies. However, it raises the possibility that projections are simply exaggerating the situation.

Thanks to these expenditures and a well-defined expansion plan, Greggs has produced substantial returns for its owners.

For the 2023 fiscal year, Greggs reported record yearly sales of £1.8 billion and a profit before taxes of £188.3 million.

The company also disclosed a significant capital investment program aimed at enhancing its manufacturing capacity and expanding its capacity to accommodate approximately 3,500 stores throughout the United Kingdom.

UK Stock Market Today: FTSE Stock Surge

Among the top risers in the FTSE, Antofagasta PLC and Rio Tinto have shown significant gains. Antofagasta PLC saw notable gains despite no specific news being released. Rio Tinto’s positive results, which included a 1.8% increase in first-half profit, contributed to a 1% rise in its shares and may have influenced the broader market.

More significantly, there are rumours that the Anglo-Australian miner Antofagasta is eyeing a major opportunity in the copper industry, further boosting investor confidence.

The Footsie has continued to rise, hitting a two-month peak of nearly 8,374 following a 1.2% increase. This is the highest value for the London standard since May 22nd, topping 8,368.

HSBC Makes a £3 Billion Buyback

Following a largely flat first half of the year, HSBC Holdings PLC announced an additional interim dividend and a £3 billion share buyback.

For the first half of 2024, the £0.10 per share dividend will equate to 20 cents, unchanged from the previous year. The share buyback is anticipated to be finished in three months.

The bank, with a focus on Asia, reported a first-half pre-tax profit of $21.6 billion, which was marginally lower than the same period last year, even though revenue increased 1% to $37.3 billion and certain “strategic transactions” had a net positive revenue impact of $0.2 billion.

The second quarter’s $16.5 billion in revenues exceeded analysts’ expectations, and the quarter’s $8.9 billion profit before taxes was significantly more than the $7.8 billion they had predicted.

Despite being lower than the 1.53% consensus estimate, the net interest margin improved from 1.7% to 1.62% a year ago due to an increase in the finance cost of average profit liabilities. These developments are significant for the stock market news UK, as they may influence investor sentiment and market trends.

FTSE 250 Share Price

  • Value: 21,572.34
  • Net Variation: 139.83
  • High/Low: 21,649.47 / 21,430.07
  • Previously closed price: 21,432.51
  • 52WK range: 16,783.09 – 21,432.51
  • Launch date: October 12th 1992
  • Constituents number: 250
  • Net MCap: 324,478
  • Dividend Yield: 3.35%
  • Average: 1,298
  • Largest: 4,059
  • Smallest: 81
  • Median: 1,085

FTSE 100 Share Price

  • Value: 8,390.33
  • Previous Close: 8,292.35
  • Open Price: 8,292.35
  • Day low: 8,235.55
  • Day High: 8,297.92
  • 52-week low: 7,215.76
  • 52-week high: 8,474.41

In summary, today’s gains on the stock market news UK are remarkable, as the FTSE 100 and FTSE 250 indices both saw an increase. Mining stocks, especially in the FTSE 100, have primarily driven these gains. Major indices have also increased throughout Europe, indicating an optimistic trend in the market.

While GSK continues to face difficulties even after increasing its earnings projections, Greggs has shown remarkable growth in both its stock price as well as profitability. Despite a little fluctuation in its profit margins, HSBC’s announcement of a significant share buyback and dividend demonstrates the strength of its financial position.

The post Stock Market News UK Update: FTSE 100 & 250 Rise appeared first on FinanceBrokerage.

Restaurant chain Hooters of America filed for bankruptcy protection in Texas on Monday, seeking to address its $376 million debt by selling all of its company-owned restaurants to a franchise group backed by the company’s founders.

Hooters, like other casual dining restaurants, has struggled in recent years due to inflation, the high costs of labor and food and declining spending by cash-strapped American consumers. The company currently directly owns and operates 151 locations, with another 154 restaurants operated by franchisees, primarily in the United States.

The privately-owned company, which shares a private equity owner with recently-bankrupt TGI Fridays, intends to sell all corporate-owned locations to a buyer group comprised of two existing Hooters franchisees, who operate 30 high-performing Hooters locations in the U.S., mainly in Florida and Illinois.

Hooters did not disclose the purchase price of the transaction, which must be approved by a U.S. bankruptcy judge before it becomes final.

Founded in 1983, Hooters became famous for its chicken wings and its servers’ uniform of orange shorts and low-cut tank tops.

The buyer group is backed by some of Hooters’ original founders, and it pledged to take Hooters “back to its roots.”

“With over 30 years of hands-on experience across the Hooters ecosystem, we have a profound understanding of our customers and what it takes to not only meet, but consistently exceed their expectations,” said Neil Kiefer, a member of the buyer group and the current CEO of the original Hooters’ location in Clearwater, Florida.

Hooters said it expects to complete the deal and emerge from bankruptcy in three to four months. The company has lined up about $35 million in financing from its existing lender group to complete the bankruptcy transaction.

Casual dining restaurants have been hammered by rising costs in 2024, with well-known chains like TGI Fridays, Red Lobster, Bucca di Beppo, and Rubio’s Coastal Grill all filing for bankruptcy last year.

Restaurant prices have risen about 30% in the last 5 years, outpacing consumer prices overall, according to the Federal Reserve Bank of St. Louis.

This post appeared first on NBC NEWS